Donald L. Drakeman was the founding CEO of the US biotech company that pioneered the development of the checkpoint inhibitor cancer treatments recognized in the Nobel Prize for Medicine 2018. He is Distinguished Research Professor in the Program on Constitutional Studies at the University of Notre Dame.
~~tag-text~~
Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the ... SEE MORE